Incidence of uveitis and macular edema among patients taking fingolimod 0.5 mg for multiple sclerosis

Journal of Ophthalmic Inflammation and Infection

Scott Joseph Sonne¹  Bradley Thomas Smith² 

[1] St. Louis University School of Medicine, St. Louis, USA;The Retina Institute in St. Louis, 2201 S Brentwood Blvd, 63144, St. Louis, MO, USA;Department of Ophthalmology and Visual Sciences, Washington University, St. Louis, USA;

关键词: Cystoid macular edema;    Macular edema;    Uveitis;    Multiple sclerosis;    Acute macular neuroretinopathy;    Fingolimod;    Gilenya;   

DOI  :  10.1186/s12348-020-00215-1

来源: Springer

【 摘 要 】

BackgroundPatients with multiple sclerosis (MS) have a higher incidence of uveitis compared with the general population. Fingolimod, a first line disease modifying drug used in multiple sclerosis, may cause macular edema and thus requires ophthalmic examination. However, murine models and anecdotal reports suggest fingolimod may reduce the incidence of uveitis.PurposeTo report the incidence of uveitis and macular edema among those on fingolimod 0.5 mg (Gilenya®) therapy for multiple sclerosis (MS).MethodsRetrospective review of patients on fingolimod who developed uveitis and/or macular edema.ResultsNo patients had an occurrence or history of uveitis. Four of the 188 (2.13%) patients developed macular edema without ocular inflammation. One of the 188 (0.53%) patients developed Acute Macular Neuroretinopathy.ConclusionPatients taking fingolimod have a lower incidence of uveitis than expected in a population of MS patients.

【 授权许可】

CC BY